Following The Patents: Covid-19 & Medical Tyranny
Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.
The
National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit. (Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”
(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was
ever detected in humans!
Against
this backdrop, they noted the unusual patent prosecution efforts of the CDC,
when on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This
legality did not deter CDC in their efforts. Their application, updated in
2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not
licensed by their patent from manipulating SARS CoV, developing tests or kits
to measure SARS coronavirus in humans or working with their patented virus for
therapeutic use. Work associated with this virus by their select collaborators
included considerable amounts of chimeric engineering, gain-of-function
studies, viral characterization, detection, treatment (both vaccine and
therapeutic intervention), and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted
without permission or infringement.
It
was noted that gain-of-function specialist, Dr. Ralph Baric, was both the
recipient of millions of dollars of U.S. research grants from several federal
agencies but also sat on the World Health Organization’s International
Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study
Group (CSG). In this capacity, he was both responsible for determining
“novelty” of clades of virus species but directly benefitted from determining
declarations of novelty in the form of new research funding authorizations and
associated patenting and commercial collaboration. Together with CDC, NIAID, WHO,
academic and commercial parties (including Johnson & Johnson; Sanofi and
their several coronavirus patent holding biotech companies; Moderna; Ridgeback;
Gilead; Sherlock Biosciences; and, others), a powerful group of interests
constituted what we would suggest are “interlocking directorates” under U.S.
anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.
35 U.S.C. § 101
Section
101 of the Patent Act: "Whoever
invents or discovers any new and useful ... composition of matter, or any new
and useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title." 35 U.S.C. § 101.
We
have "long held that this provision contains an important implicit
exception[:] Laws of nature, natural phenomena, and abstract ideas are not
patentable." Mayo, 566 U.S., at , 132 S.Ct., at 1293 (internal
quotation marks and brackets omitted). Rather, "`they are the basic tools
of scientific and technological work'" that lie beyond the domain of
patent protection. Id., at ,
132 S.Ct., at 1293. As the Court has explained, without this exception, there
would be considerable danger that the grant of patents would "tie up"
the use of such tools and thereby "inhibit future innovation premised upon
them." Id., at _, 132
S.Ct., at 1301. This would be at odds with the very point of patents, which
exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct.
2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and
"`manifestations... of nature [are] free to all men and reserved
exclusively to none'").(Source: Association
for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))
In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.
When
they filed their patent application on April 25, 2003, their first claim (and
the only one that survived to ultimate issuance over the objection of the
patent examiner in 2006 and 2007) was the genome for SARS CoV.
While
this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC
insist on its granting over non-final and final rejections, but they also
continued to pay maintenance fees on the patent after the 2013 Supreme Court
decision confirmed that it was illegal.
In
addition, the CDC patented the detection of SARS CoV using a number of methods
including reverse transcription polymerase chain reaction (RT-PCR). With this
patent, they precluded anyone outside of their licensed or conspiring interest
from legally engaging in independent verification of their claim that they had
isolated a virus, that it was a causative agent for SARS, or that any therapy
could be effective against the reported pathogen.
It
is important to note that the CDC’s patent applications were also rejected in
non-final and final rejections for ineligibility under 35 U.S.C. § 102 for
being publicly disclosed prior to their own filing.
In the first non-final rejection, the USPTO stated that the CDC’s genome was
published in four Genbank accession entries on April 14, 18, and 21, 2003 with
identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO
Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew,
and failed to disclose evidence that the CDC patent was illegal, based on work
he had funded in the years leading up to the SARS outbreak.
After
seeking an illegal patent, petitioning to override the decision of an examiner
to reject it, and ultimately prevailing with the patent’s grant, the CDC lied
to the public by stating they were controlling the patent so that it would be
“publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0)
Tragically, this public statement is falsified by the simple fact that their
own publication in Genbank had, in fact, made it public domain and thereby
unpatentable. This fact, confirmed by patent examiners, was overridden by CDC
in a paid solicitation to override the law.
While
not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is
detailed below. Of note, however, is his willful and deceptive use of the term
“vaccine” in patents and public pronouncements to pervert the meaning of the
term for the manipulation of the public.
In the 1905 Jacobson v. Mass case, the court was clear that a
PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor
Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts,
197 U.S. 11 (1905), the court held that the context for their opinion rested on
the following principle:
“This court has more than once recognized it as a fundamental
principle that 'persons and property are subjected to all kinds of restraints
and burdens in order to secure the general comfort, health, and prosperity of
the state…”
The Moderna and Pfizer “alleged vaccine” trials have explicitly
acknowledged that their gene therapy technology has no impact on viral
infection or transmission whatsoever and merely conveys to the recipient the
capacity to produce an S1 spike protein endogenously by the introduction of a
synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and
the Supreme Court’s determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV
vaccine made the following statement supporting their rejection of his bogus
"invention"
18 U.S.C. §2339 C et seq. – Funding and Conspiring to
Commit Acts of Terror
Indirectly, unlawfully, and willfully provides or collects funds
with the intention that such funds be used, or with the knowledge that such
funds are to be used, in full or in part, in order to carry out—
- an act
which constitutes an offense within the scope of a treaty specified in
subsection (e)(7), as implemented by the United States, or
- any
other act intended to cause death or serious bodily injury to a civilian,
or to any other person not taking an active part in the hostilities in a
situation of armed conflict, when the purpose of such act, by its nature
or context, is to intimidate a population, or to compel a government or
an international organization to do or to abstain from doing any act….
By
no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the
association of SARS with bioterror potential. Leveraging the fear of the
anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic
terror had directed towards his budget. He specifically stated that NIAID was
actively funding research on a “SARS Chip” DNA microarray to rapidly detect
SARS (something that was not made available during the current “pandemic”) and
two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his
employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least
one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/
) This team, part of the Vaccine Research Center at NIAID, was primarily
focused on HIV vaccine development but was tasked to identify SARS vaccine
candidates as well. Working in collaboration with Sanofi, Scripps Institute,
Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as
a primary intervention for several designated “infectious diseases” precluded proven
therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)
The
CDC and NIAID led by Anthony Fauci entered into trade among States (including,
but not limited to working with EcoHealth Alliance Inc.) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences) through the 2014 et seq National Institutes of Health Grant
R01AI110964 to exploit their patent rights. This research was known to
involve surface proteins in coronavirus that had the capacity to directly
infect human respiratory systems. In flagrant violation of the NIH
moratorium on gain of function research, NIAID and Ralph Baric persisted in
working with chimeric coronavirus components specifically to amplify the
pathogenicity of the biologic material.
By
October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein
was described in NIAID’s funded work in China.
This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth
Alliance. This work, funded under R01AI079231, was pivotal in isolating and
manipulating viral fragments selected from sites across China which contained
high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et
al. Isolation and characterization of a bat SARS-like coronavirus that uses
the ACE2 receptor. Nature 503, 535–538 (2013).)
By
March 2015, both the virulence of the S1 spike protein and the ACE II receptor
was known to present a considerable risk to human health. NIAID,
EcoHealth Alliance and numerous researchers lamented the fact that the public
was not sufficiently concerned about coronavirus to adequately fund their
desired research.(Source: Forum on Medical and Public Health Preparedness for
Catastrophic Events; Forum on Drug Discovery, Development, and Translation;
Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global
Health; Institute of Medicine; National Academies of Sciences, Engineering, and
Medicine. Rapid Medical Countermeasure Response to Infectious Diseases:
Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector
Partnerships: Workshop Summary. Washington (DC): National Academies Press (US);
2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)
Dr.
Peter Daszak of EcoHealth Alliance offered the following assessment:
“Daszak
reiterated that, until an infectious disease crisis is very real, present, and
at an emergency threshold, it is often largely ignored. To sustain the funding
base beyond the crisis, he said, we need to increase public understanding of
the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key
driver is the media, and the economics follow the hype. We need to use that
hype to our advantage to get to the real issues. Investors will respond if they
see profit at the end of process, Daszak stated.”
Economics
will follow the hype.
The
CDC and NIAID entered into trade among States (including, but not limited to
working with University of North Carolina, Chapel Hill) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place
during a time when the work being performed was prohibited by the United States
National Institutes of Health.
The
public was clearly advised of the dangers being presented by NIAID-funded
research by 2015 and 2016 when the Wuhan Institute of Virology material was
being manipulated at UNC in Ralph Baric’s lab.
“The
only impact of this work is the creation, in a lab, of a new, non-natural
risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at
Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are
long-standing critics of gain-of-function research.
In
their paper, the study authors also concede that funders may think twice about
allowing such experiments in the future. "Scientific review panels may
deem similar studies building chimeric viruses based on circulating strains too
risky to pursue," they write, adding that discussion is needed as to
"whether these types of chimeric virus studies warrant further
investigation versus the inherent risks involved”.
But
Baric and others say the research did have benefits. The study findings “move
this virus from a candidate emerging pathogen to a clear and present danger”,
says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the
EcoHealth Alliance, an international network of scientists, headquartered in
New York City, that samples viruses from animals and people in
emerging-diseases hotspots across the globe.
Studies
testing hybrid viruses in human cell culture and animal models are limited in
what they can say about the threat posed by a wild virus, Daszak agrees. But he
argues that they can help indicate which pathogens should be prioritized for
further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )
Knowing
that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID,
and their funded laboratories and commercial partners) had patents on each
proposed element of medical counter measures and their funding, Dr. Fauci, Dr.
Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to
commit acts of terror on the global population – including the citizens of the
United States – when, in September 2019, they published the following mandate:
“Countries,
donors and multilateral institutions must be prepared for the worst. A
rapidly spreading pandemic due to a lethal respiratory pathogen (whether
naturally emergent or accidentally or deliberately released) poses
additional preparedness requirements. Donors and multilateral institutions must
ensure adequate investment in developing innovative vaccines and therapeutics,
surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical
interventions. All countries must develop a system for immediately sharing
genome sequences of any new pathogen for public health
purposes along with the means to share limited medical countermeasures across
countries.
Progress
indicator(s) by September 2020
A. Donors and countries commit and
identify timelines for: financing and development of a universal influenza
vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its
Member States develop options for standard procedures and timelines for sharing
of sequence data, specimens, and medical countermeasures for pathogens other
than influenza.
B. Donors, countries and multilateral
institutions develop a multi-year plan and approach for strengthening R&D
research capacity, in advance of and during an epidemic.
C. WHO, the United Nations Children’s
Fund, the International Federation of Red Cross and Red Crescent Societies,
academic and other partners identify strategies for increasing capacity and
integration of social science approaches and researchers across the entire
preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf
(page 8) )
As
if to confirm the utility of the September 2019 demand for “financing and development
of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019,
Dr. Fauci began gloating that his fortunes for additional funding were likely
changing for the better. In a February 2020 interview in STAT, he
was quoted as follows:
““The
emergence of the new virus is going to change that figure, likely considerably,
Fauci said. “I don’t know how much it’s going to be. But I think it’s going to
generate more sustained interest in coronaviruses because it’s very clear that
coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting
in death of American Citizens
Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded
the definition of terrorism to cover "domestic," as opposed to
international, terrorism. A person engages in domestic terrorism if they do an
act "dangerous to human life" that is a violation of the criminal
laws of a state or the United States, if the act appears to be intended to: (i)
intimidate or coerce a civilian population; (ii) influence the policy of a
government by intimidation or coercion;
Dr.
Anthony Fauci has intimidated and coerced a civilian population and sought to
influence the policy of a government by intimidation and coercion.
With
no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives
) Professor Neil Ferguson’s computer simulation derived claims that,
“The
world is facing the most serious public health crisis in generations. Here we
provide concrete estimates of the scale of the threat countries now face.
“We
use the latest estimates of severity to show that policy strategies which aim
to mitigate the epidemic might halve deaths and reduce peak healthcare demand
by two-thirds, but that this will not be enough to prevent health systems being
overwhelmed. More intensive, and socially disruptive interventions will
therefore be required to suppress transmission to low levels. It is likely such
measures – most notably, large scale social distancing – will need to be in
place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)
Reporting
to the President that as many as 2.2 million deaths may result from a pathogen
that had not yet been isolated and could not be measured with any accuracy, Dr.
Fauci intimidated and coerced the population and the government into reckless,
untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source:
https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline)
Neither the Imperial College nor the “independent” Institute for Health
Metrics and Evaluation (principally funded by the Bill and Melinda Gates
Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement)
had any evidence of success in estimating previous burdens from
coronavirus but, without consultation or peer-review, Dr. Fauci adopted their
terrifying estimates as the basis for interventions that are explicitly against
medical advice.
a. The imposition of social
distancing was based on computer simulation and environmental models with NO
disease transmission evidence whatsoever.
b. The imposition of face mask
wearing was directly against controlled clinical trial evidence and against the
written policy in the Journal of the American Medical Association.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)
c. In both the Imperial College and
the IHME simulations, quarantines were modeled for the sick, not the
healthy.
Insisting
on vaccines while blockading the emergency use of proven pharmaceutical
interventions may have contributed to the death of many patients and otherwise healthy
individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)
Using
the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively
suppressed proven medical countermeasures used by, and validated in scientific
proceedings, that offered alternatives to the products funded by his conspiring
entities for which he had provided direct funding and for whom he would receive
tangible and intangible benefit.
18 U.S.C. § 1001 – Lying to Congress
Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—
- falsifies, conceals, or covers up by any trick, scheme, or
device a material fact;
- makes any materially false, fictitious, or fraudulent
statement or representation; or
- makes or uses any false writing or document knowing the
same to contain any materially false, fictitious, or fraudulent
statement or entry;
shall
be fined under this title, imprisoned not more than 5 years or, if the offense
involves international or domestic terrorism (as defined in section 2331),
imprisoned not more than 8 years, or both. If the matter relates to an offense
under chapter 109A, 109B, 110, or 117, or section 1591, then the term of
imprisonment imposed under this section shall be not more than 8 years.
On
October 22, 2020, the United States Government Accountability Office (GAO)
published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly
Report More Information about the Licensing of Its Intellectual Property.
In this document, the
authors reported that the National Institutes of Health (NIH) received, “up to
$2 billion in royalties from its contributions to 34 drugs sold from
1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)
A
casual review of the NIH Office of Technology Transfer report of active
licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics)
appears to conflict with the GAO report on several important facts.
Conspicuously absent from the GAO report are over 30 patents associated with
active compounds generating billions of dollars in revenue. Why would it be
that the GAO and the NIH couldn’t agree on something as simple as drugs
generating income for NIH?
Since
the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally
funded research has been an economic bonanza for U.S. universities, federal
agencies, and their selected patronage. For the first decade following Bayh
Dole, NIH funding
doubled from $3.4 billion to $7.1 billion. A decade later, it
doubled again to $15.6 billion. In the wake of September 2001, the
National Institute for Allergy and Infectious Diseases (NIAID) saw its direct
budget increase over 300%, without accounting for DARPA, funds of as much as
$1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41
billion.
What
has become of the $763 billion of taxpayer funds allocated to making America
healthier since inventors have been commercially incentivized? Who has been
enriched?
The
answer, regrettably, is that no accountability exists to answer these questions.
The NIH is the named owner of at least 138 patents since 1980.
The
United States Department of Health and Human Services is the named owner of at
least 2,600 patents.
NIAID
grants or collaboration have resulted in 2,655 patents and patent applications
of which only 95 include an assignment to the Department of Health and Human
Services as an owner. Most of these patents are assigned to universities
thereby making the ultimate commercial beneficiaries entirely opaque. One
of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly
reporting close affiliation with NIAID, is not referenced in the NIH GAO
report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing
its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before
exiting to commercial ventures. While their technology is clearly derived
from NIAID science, the company reports revenue from NIAID but no royalty or
commercial payments to NIH or any of its programs.
NIAID’s
Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents.
None of them are reported in NIAID, NIH, or GAO reports of active licensing
despite the fact that Dr. Fauci reportedly was compelled to get paid for his
interleukin-2 “invention” – payments he reportedly donated to an unnamed
charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)
Of
the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange
book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are
listed. Furthermore, none of the NIAID patents are listed despite clear
evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of
Johnson & Johnson) have generated over $2 billion annually from sales that
were the direct result of NIAID funded science. Missing from the GAO report
are 2 patents for Velclade® which has been generating sales in excess of $2.18
billion annually for several years. None of the patents for Yescarta® are
listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO
report. None of the Kepivance® patents are listed in the GAO report. In
violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in
the GAO report fail to disclose government interest despite being the direct
result of NIH funding.
Dr.
Anthony Fauci’s Own Patent Track Record:
US
Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent
interleukin-2 therapy:
A
method for activating a mammalian immune system entails a series of IL-2
administrations that are affected intermittently over an extended period. Each
administration of IL-2 is sufficient to allow spontaneous DNA synthesis in
peripheral blood or lymph node cells of the patient to increase and peak, and
each subsequent administration follows the preceding administration in the
series by a period of time that is sufficient to allow IL-2 receptor expression
in peripheral or lymph node blood of the patient to increase, peak and then
decrease to 50% of peak value. This intermittent IL-2 therapy can be combined
with another therapy which targets a specific disease state, such as an anti-retroviral
therapy comprising, for example, the administration of AZT, ddI or interferon
alpha. In addition, IL-2 administration can be employed to facilitate in situ
transduction of T-cells in the context of gene therapy. By this approach the
cells are first activated in vivo via the aforementioned IL-2 therapy, and
transduction then is affected by delivering a genetically engineered retroviral
vector directly to the patient.
This
application is a continuation of U.S. patent application Ser. No. 08/487,075,
filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S.
patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S.
Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May
26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage
filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of
which are incorporated herein by reference.
Filed
May 19, 1993
Issued
a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998
and April 12, 1999. Reduced and modified claims granted May 8, 2000.
This
family of patents was the basis of Fauci’s lie to the British Medical
Journal in which he falsely stated:
“Dr
Anthony Fauci told the BMJ that as a government employee he was required by law
to put his name on the patent for the development of interleukin 2 and was also
required by law to receive part of the payment the government received for use
of the patent. He said that he felt it was inappropriate to receive payment and
donated the entire amount to charity.”
US Patent 6,911,527 - HIV related peptides:
This
invention is the discovery of novel specific epitopes and antibodies associated
with long term survival of HIV-1 infections. These epitopes and antibodies have
use in preparing vaccines for preventing HIV-1 infection or for controlling
progression to AIDS.
Filed
May 6, 1999
Rejected
as unpatentable January 22, 2003. Issued with a final rejection on July 15,
2004 after submitting reconsideration requests. Modified and restricted claims
allowed September 29, 2004.
US
Patent 7,368,114 - Fusion protein including of CD4:
Novel
recombinant polypeptides are disclosed herein that include a CD4 polypeptide
ligated at its C-terminus with a portion of an immunoglobulin comprising a
hinge region and a constant domain of a mammalian immunoglobulin heavy chain.
The portion or the IgG is fused at its C-terminus with a polypeptide comprising
a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara
tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also
disclosed herein are methods for using these CD4 fusion proteins.
Filed
October 24, 2002
Rejected
as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings
February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants
further narrowed the construction of what was clearly not a patent and the
USPTO granted less than half the claims that had been sought in the original
filing.
US
Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the
interaction between HIV GP120 and .alpha.4.beta.7 integrin:
Methods
are provided for the treatment of a HIV infection. The methods can include
administering to a subject with an HIV infection a therapeutically effective
amount of an agent that interferes with the interaction of gp120 and .alpha.4
integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist,
thereby treating the HIV infection. In several examples, the .alpha.4 integrin
antagonist is a monoclonal antibody that specifically binds to a .alpha.4,
.beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino
acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or
infection. The methods include contacting a cell with an effective amount of an
agent that interferes with the interaction of gp120 and .alpha.4 integrin, such
as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods
are provided for determining if an agent is useful to treat HIV.
Rejected
May 22, 2017 as Double Patenting. In their response, the applicants acknowledge
the illegal act and seek only those components of their application that extend
beyond the life of the issued patents. On October 11, 2017, the limited claims
were issued.
A
sample of the convoluted flow of funds that evades public disclosure.
U.S.
Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby,
British Columbia. In their patent, they disclose that their research was
supported by a grant from the National Institute of Allergy and Infectious
Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was
awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam
Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics |
Technology Networks)
In
2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes
including a $1 billion damages claim for “relentless and egregious”
misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest
priority of November 10, 2008, there is no public record stating Tekmira as the
beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle
technology developed from this grant is the technology now used in the Moderna
COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a
license to technology from Arbutus – formerly Tekmira – which has accused
Acuitas of misappropriating trade secrets and licensing them to Moderna and
Pfizer’s collaboration with BioNTech.
Additional
references can be found at:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22
15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity
Every
contract, combination in the form of trust or otherwise, or conspiracy, in
restraint of trade or commerce among the several States, or with foreign
nations, is declared to be illegal. Every person who shall make any contract or
engage in any combination or conspiracy hereby declared to be illegal shall be
deemed guilty of a felony, and, on conviction thereof, shall be punished by
fine not exceeding $100,000,000 if a corporation, or, if any
other
person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said
punishments, in the discretion of the court.
The
National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit.(Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was ever
detected in humans.
Against
this backdrop, we noted the unusual patent prosecution efforts of the CDC, when
on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did
not deter CDC in their efforts. Their application, updated in 2007, ultimately
issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS
coronavirus in humans or working with their patented virus for therapeutic use.
Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral
characterization, detection, treatment (both vaccine and therapeutic intervention),
and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted without
permission or infringement.
We
noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient
of millions of dollars of U.S. research grants from several federal agencies
but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In
this capacity, he was both responsible for determining “novelty” of clades of
virus species but directly benefitted from determining declarations of novelty
in the form of new research funding authorizations and associated patenting and
commercial collaboration. Together with CDC, NIAID, WHO, academic and
commercial parties (including Johnson & Johnson; Sanofi and their several
coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead;
Sherlock Biosciences; and, others), a powerful group of interests constituted
what we would suggest are “interlocking directorates” under U.S. anti-trust
laws.
·
1986-1990 NIAID Grant AI
23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant
Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
The
paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
·
1990 Pfizer files U.S.
Patent 6,372,224 on a vaccine for the S-protein on coronavirus November
14, 2000 which was abandoned April 2010 making it public domain.
· 1990s Work focused on CoV association with cardiomyopathy (see above)
Early
reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
·
2000 Ralph Baric AI23946
and GM63228 from the National Institutes of Health actively working recombinant
CoV
·
2001 National Institute
of Health, Allergy and Infectious diseases. “Reverse Genetics with a
Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total
costs/yr. RS Baric, PI
·
2002 Asia CoV SARS
outbreak
· 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.
Dr.
Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand
Challenges Scientific Advisory Board (served through 2010).
·
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response
and patent US7,151,163 https://www.sbir.gov/node/305319
· July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana
Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to
neutralize SARS CoV. This research is supported by several NIH grants including
National Institutes of Health Grants A128785, A148436, and A1053822.
·
2004 January 6, 2004 – SARS
and Bioterrorism linked at Bioterrorism and Emerging Infectious
Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At
this conference, the term “The New Normal” was introduced by Merck
FAUCI
AND BARIC start making money!!! National Institutes of Health,
Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7
million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project
develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV
replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV
to mice, producing a pathogenic mouse model for SARS-CoV infection.
National
Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS
Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09.
$2.1 million
·
November 22, 2004
University of Hong Kong patents SARS associated spike protein on CoV and
pursues patent US 7,491,489
·
2005 DARPA gets in on the
game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies,
June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Review
timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U
and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
·
2008 Biodefense Grant U54
AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
·
2009 Biodefense Grant U54
AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)
Patent
issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued
patents.
·
August 6, 2010, Moderna (prior to its establishment) files U.S.
Patent 9,447,164 which attracted the investment of (and “inventorship” for)
venture capitalists at Flagship Ventures. This patent grew out of the work of
Dr. Jason P. Schrum of Harvard Medical School supported by National Science
Foundation Grant #0434507. While the application claims priority to August 2010, the application
didn’t get finalized until October, 2015. On November 4, 2015, the USPTO
issued a non-final rejection on this original patent rejecting all claims.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507
with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
·
2011 Crucell joined the
Janssen Pharmaceutical Companies of Johnson & Johnson in February taking
with it all of its SARS technology.
Biodefense
Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill
(non-competitive grant from NIAID)
·
2012 MERS isolated in
Egypt
Biodefense
Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive
grant from NIAID)
·
2013 Biodefense Grant U54
AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435
·
2015 Moderna signs a
vaccine development agreement with NIAID and executes it with the lead on the
mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
·
2016 NIH through Scripps
Institute and Dartmouth College file patent application WO 2018081318A1
“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology
that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en
Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person
at NIH that Moderna “e-mailed” to get the sequence for SARS
CoV-2
according to Moderna’s report here (“In January
2020, once it was discovered that the infection in Wuhan was caused by a novel
coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the
Vaccine Research Center at the National Institutes of Health, asking him to
send the genetic sequence for the virus.”)
https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In
addition, co-inventor Jason McLellan worked with Graham on a vaccine patent
jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
·
2017 August – Sanofi buys
Protein Science Corp with considerable SARS patent holdings
·
2018 June – Sanofi buys
Ablynx with considerable SARS patent holdings
·
2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by
Open Philanthropy – the same organization that would be the financial sponsor
of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan
in October 2019.
15 U.S.C. §8 – Market Manipulation and Allocation
Every combination, conspiracy, trust, agreement, or contract is
declared to be contrary to public policy, illegal, and void when the same is
made by or between two or more persons or corporations, either of whom, as
agent or principal, is engaged in importing any article from any foreign
country into the United States, and when such combination, conspiracy, trust,
agreement, or contract is intended to operate in restraint of lawful trade, or
free competition in lawful trade or commerce, or to increase the market price
in any part of the United States of any article or articles imported or
intended to be imported into the United States, or of any manufacture into
which such imported article enters or is intended to enter. Every person who
shall be engaged in the importation of goods or any commodity from any foreign
country in violation of this section, or who shall combine or conspire with
another to violate the same, is guilty of a misdemeanor, and on conviction
thereof in any court of the
United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.
Through
non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of
the Bio-Safety Level 4 laboratory locations, to the setting of prices for
Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S.
Department of Health and Human Services have been involved in allocating
Federal funds to conspiring parties without independent review.
Around
March 12, 2020, in an effort to enrich their own economic interests by way of
securing additional funding from both Federal and Foundation actors, the CDC
and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by
capricious symptom presentation alone. Forcing the public to rely on The
COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates
Foundation and presented by a media outlet (The Atlantic) – not a public health agency – Dr. Fauci used
fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive
PCR tests in the living while insisting that COVID deaths be counted by
symptoms alone. This perpetuated a market demand for his desired vaccine agenda
which was recited by him and his conspiring parties around the world until the
present. Not surprisingly, this was necessitated by the apparent fall in cases
that constituted Dr. Fauci’s and others’ criteria for depriving citizens of
their 1st Amendment rights.
15 U.S.C. § 19 – Interlocking Directorates
No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—
- engaged in whole or in part in commerce; and
- by virtue of their business and location of operation,
competitors, so that the elimination of competition by agreement between
them would constitute a violation of any of the antitrust laws; if each
of the corporations has capital, surplus, and undivided profits
aggregating more than $10,000,000 as adjusted pursuant to paragraph (5)
of this subsection.
Dr. Fauci is on the Leadership Council
of the Bill and Malinda Gates Global Vaccine Action Plan
Dr.
Fauci while controlling the economic dispensation of Federal research funding,
Dr. Fauci has been, and continues to be, on the World Health Organization’s
Global Preparedness Monitoring Board. He is joined on this board by the
conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias
and the State Council of China’s Dr. George
F.
Gao of the Chinese CDC. This GPMB stipulated that all member states must take
part in a global simulation of the release of a respiratory pathogen.
Dr.
Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4
facility and sits on the International Committee on Taxonomy of Virus Coronaviridae
Working Group tasked to confirm the presence of absence of the pathogen for
which he is directly compensated.
As
referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous
undisclosed commercial relationships exist between funded researchers, their
funding agencies, and commercial interests in which disclosed and undisclosed
commercial terms exist. A complete list of all potential implicated parties
is listed in the section below entitled “The Commercial Actors”.
It
appears that during the period of patent enforcement and after the Supreme
Court ruling confirming that patents on genetic material were illegal, the CDC
and National Institute of Allergy and Infectious Diseases led by Anthony Fauci
(hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade
among States (including, but not limited to working with Ecohealth Alliance
Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology
and the Chinese Academy of Sciences) through the 2014 et seq National
Institutes of Health Grant R01AI110964 to exploit their patent rights.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on genetic material was illegal,
the CDC and National Institute of Allergy and Infectious Diseases (hereinafter
“NIAID”) entered into trade among States (including, but not limited to working
with University of North Carolina, Chapel Hill) and with foreign nations
(specifically, the Wuhan Institute of Virology and the Chinese Academy of
Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on generic material was illegal,
the CDC and NIAID entered into trade among States (including, but not limited
to working with University of North Carolina, Chapel Hill) and with foreign
nations to conduct chimeric construction of novel coronavirus material with
specific virulence properties prior to, during, and following the determination
made by the National Institutes for Health in October 17, 2014 that this work
was not sufficiently understood for its biosecurity and safety standards.
In
this inquiry, it is presumed that the CDC and its associates were: a) fully
aware of the work being performed using their patented technology; b) entered
into explicit or implicit agreements including licensing, or other consideration;
and, c) willfully engaged one or more foreign interests to carry forward the
exploitation of their proprietary technology when the U.S. Supreme Court
confirmed that such patents were illegal and when the National Institutes of
Health issued a moratorium on such research.
Reportedly,
in January 2018, the U.S. Embassy in China sent investigators to Wuhan
Institute of Virology and found that, “During interactions with scientists
at the WIV laboratory, they noted the new lab has a serious shortage of
appropriately trained technicians and investigators needed to safely operate
this high-containment laboratory.” The Washington Post reported that this
information was contained in a cable dated 19 January 2018. Over a year later,
in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army
Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and
ordered it closed after alleging that their inspection found biosafety hazards.
A report in the journal Nature in 2003 (423(6936): 103) reported cooperation
between CDC and USAMRIID on coronavirus research followed by considerable
subsequent collaboration. The CDC, for what appear to be the same type of
concern identified in Wuhan, elected to continue work with the Chinese
government while closing the U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.
35 U.S.C. §200 - 206 – Disclosure of Government Interest
35 U.S.C. §202 (c)(6)
An
obligation on the part of the contractor, in the event a United States patent
application is filed by or on its behalf or by any assignee of the contractor,
to include within the specification of such application and any patent issuing
thereon, a statement specifying that the invention was made with Government
support and that the Government has certain rights in the invention.
Over 5000 patents and patent
applications have included reference to SARS Coronavirus dating back to
priority dates of 1998. They are summarized below.
On
July 23, 2020, the Patent Trial and Appeal Board of the United States Patent
and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent
8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by
Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver
an mRNA vaccine. Some of the core technology was based on work originally done
at the University of British Columbia and was first licensed in 1998.
mRNA-1273
– the experimental vaccine developed by Moderna for COVID-19 – uses the LNP
technology that Moderna thought it had licensed from Acuitas Therapeutics Inc.,
a firm developed by a former principal of Arbutus’ prior company Tekmira. That
license did not authorize Moderna to use the technology for the COVID-19
vaccine.
M·CAM
and Knowledge Ecology International have independently confirmed that Moderna
has violated U.S. law in failing to disclose the U.S. government’s funding
interest in their patents and patent applications.
While this negligence impacts all of Moderna’s over 130 granted U.S. patents,
it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the
patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open
reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein
subunit formulated in a lipid nanoparticle.” The specific claims addressing the
pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS
CoV-2 outbreak! Both the patent and the DARPA funding
for the technology were disclosed in scientific publication (New England
Journal of Medicine) but the government funds were not acknowledged in the
patent.
In 2013, the Autonomous Diagnostics to Enable Prevention and
Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for
the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was
W911NF-13-1-0417. The company used that technology to develop its
COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source:
https://crsreports.congress.gov/product/pdf/IN/IN11446)
Under
the Federal Acquisition Regulation (FAR) rules, contractor to the Federal
Government must provide information regarding intellectual property
infringement issues as part of their contract. Under FAR §27.201-1(c) and (d),
the Government both requires a notice of infringement or potential infringement
as well as retention of economic liability for patent infringements. Specifically,
in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its
officers, agents, and employees against liability, including costs for
infringement of any United States Patent…”. In addition to the patents cited by
the USPTO in their examination of ‘600, M·CAM has identified fourteen other
issued patents preceding the ‘600 patent which were used by patent examiners to
limit patents arising from the same funded research including patents sought by
CureVac.
In
short, while Moderna enjoys hundreds of millions of dollars of funding,
allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception,
it has been engaged in illegal patent activity and demonstrated contempt for
U.S. Patent law. To make matters worse, the U.S. Government has given it
financial backing in the face of undisclosed infringement risks potentially
contributing to the very infringement for which they are indemnified.
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial
It
is unlawful to conduct medical research (even in the case of emergency) without
a series of steps taken to:
- Establish
the research with a duly authorized and independent institutional review
board;
- Secure
informed consent of all participants including a statement of risks and
benefits; and,
- Engage
in consultation with the community in which the study is to be conducted.
Dr.
Anthony Fauci has forced upon the healthy population of the United States an
unlawful clinical trial in which the U.S. Department of Health and Human
Services are extrapolating epidemiologic data. No informed consent has been
sought or secured for any of the “medical countermeasures” forced upon the
population and no independent review board – as defined by the statute – has
been empaneled.
Through
April 2020, the official recommendation by the Journal of the American
Medical Association was unambiguous.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: Medical Masks
| Infectious Diseases | JAMA | JAMA Network)
Part
of that lack of evidence in fact showed that cloth facemasks actually increased
influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)
In
contravention to established science, States, municipalities, and
businesses have violated the legal requirements for the promulgation of medical
counter measures during a public health emergency stating a “belief” that face
masks limit the spread of SARS CoV-2. To date, not a single study has confirmed
that a mask prevented the transmission of, or the infection by SARS CoV-2.
All
parties mandating the use of facemasks are not only willfully ignoring
established science but are engaging in what amounts to a whole population clinical
trial. This conclusion is reached by the fact that facemask use and COVID-19
incidence are being reported in scientific opinion pieces promoted by the
United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)
Social
distancing of up to 6 feet has been promoted as a means of preventing
person-to-person transmission of influenza-like viruses. While one study
hypothesized that infection could happen in a 6 foot range, the study
explicitly states that person-to-person transfer was not tested and
viability of the virus at 6 feet was not even a subject of the investigation.(Source:
Werner E. Bischoff, Katrina Swett, Iris Leng,
Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient
Care, The Journal of Infectious Diseases,
Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773)
That did not stop the misrepresentation of the study to be used as the basis
for an unverified medical counter measure of social distancing. To date, no
study has established the efficacy of social distancing to modify the
transmission of SARS CoV-2. Public health officials have referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.
|
|
It
is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a
product or service can prevent, treat, or cure human disease unless you possess
competent and reliable scientific evidence, including, when appropriate, well-
controlled human clinical studies, substantiating that the claims are true at
the time they are made. As a result, every party promoting the use of face
masks is violating the FTC Act.
The Commercial Actors
SARS coronavirus is a new topic for many individuals. Since 1999,
the ability to manipulate and exploit coronavirus for a variety of purposes has
attracted the attention of individuals, institutions and commercial
organizations in public, private, and not-for-profit sectors.
The following is a list of over 4,000 patents and patent
applications filed for the express purpose of controlling some aspect of the
SARS coronavirus.
PATENT |
Title |
Owner |
Priority |
File Date |
Issue Date |
US9995706 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9995705 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9994558 |
Multicyclic
compounds and methods of using same |
Karyopharm
Therapeutics Inc. |
20- Sep- 13 |
19- Sep -14 |
12- Jun- 18 |
US9994550 |
Heterocyclic
modulators of lipid synthesis for use against cancer and viral infections |
3-V
Biosciences, Inc. |
7- Jan- 14 |
7- Jan -15 |
12- Jun- 18 |
US9993543 |
Immunogenic
compositions comprising silicified virus and methods of use |
Portland
State University |
31- Jan- 13 |
31- Jan -14 |
12- Jun- 18 |
US9982257 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
29- May -18 |
US9982241 |
Recombinant
HCMV and RHCMV vectors and uses thereof |
Oregon
Health & Science University |
14- May- 10 |
1- Oct -15 |
29- May -18 |
US9982025 |
Monomeric
griffithsin tandemers |
The
United States of America, as represented by the Secretary, Department of Health
and Human Services |
5- Jun-
13 |
5- Jun -14 |
29- May -18 |
US9981036 |
Compositions,
comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics
and methods of using the same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
12- Dec- 11 |
26- Feb -16 |
29- May -18 |
US9975885 |
Broad-spectrum
non-covalent coronavirus protease inhibitors |
PURDUE
RESEARCH FOUNDATION |
28- Apr- 16 |
28- Apr -17 |
22- May -18 |
US9974850 |
Immunogenic
compositions and uses thereof |
BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
25- Mar- 15 |
25- Mar -16 |
22- May -18 |
US9974848 |
Tetanus
toxoid and CCL3 improve DC vaccines |
Duke
University |
14- Nov- 13 |
14- Nov -14 |
22- May -18 |
US9974845 |
Combination
of vaccination and inhibition of the PD-1 pathway |
CureVac
AG |
22- Feb- 13 |
21- Feb -14 |
22- May -18 |
US9970061 |
Bioagent
detection oligonucleotides |
IBIS
BIOSCIENCES, INC. |
27- Dec- 11 |
27- Dec -12 |
15- May -18 |
US9969793 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
Biologics, Inc. |
28- Oct- 14 |
13- Nov -17 |
15- May -18 |
US9963718 |
LCMV-GP-VSV-pseudotyped
vectors and tumor-infiltrating virus- producing cells for the therapy of
tumors |
VIRATHERAPEUTICS
GMBH |
8- Oct-
08 |
7- Apr -17 |
8- May -18 |
US9963611 |
Composition
for use in decreasing the transmission of human pathogens |
Innonix
Technologies, Incorporated |
29- May- 09 |
21- May -10 |
8- May -18 |
US9963427 |
Dithiol
mucolytic agents |
PARION
SCIENCES, INC. |
23- Aug- 13 |
11- Mar -16 |
8- May -18 |
US9962439 |
Injectable
vaccine composition |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
8- May -18 |
US9957302 |
Treating
cancer with viral nucleic acid |
Mayo
Foundation for Medical Education and Research |
20- Feb- 07 |
6- Jul- 15 |
1- May -18 |
US9957300 |
Virus-like
particles, methods of preparation, and immunogenic compositions |
Emory
University |
17- May- 02 |
4- May -15 |
1- May -18 |
US9957238 |
Arylalkyl-and
aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
1- Mar -17 |
1- May -18 |
US9951317 |
Highly
efficient influenza matrix (M1) proteins |
NOVAVAX,
INC. |
11- Jul-03 |
6- Oct -16 |
24- Apr- 18 |
US9951124 |
Antibody
producing non-human mammals |
MERUS
N.V. |
27- Jun- 08 |
25- Jan -13 |
24- Apr- 18 |
US9951122 |
Antibodies
against influenza virus and methods of use thereof |
BURNHAM
INSTITUTE FOR MEDICAL RESEARCH |
6- Dec-
07 |
12- Aug -13 |
24- Apr- 18 |
US9950062 |
Compounds
and compositions as TLR activity modulators |
GLAXOSMITHKLINE
BIOLOGICALS SA |
2- Sep-
09 |
1- Sep -10 |
24- Apr- 18 |
US9945856 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
AMSTERDAM
INSTITUTE OF VIRAL GENOMICS B.V. |
18- Aug- 03 |
13- Aug -14 |
17- Apr- 18 |
US9945780 |
Use of a
fluorescent material to detect failure or deteriorated performance of a
fluorometer |
GEN-PROBE
INCORPORATED |
14- Jun- 12 |
7- Jun -13 |
17- Apr- 18 |
US9944928 |
Construction
of pool of interfering nucleic acids covering entire RNA target sequence and
related compositions |
York
Yuan Yuan Zhu |
23- Jul-07 |
2- Jul- 15 |
17- Apr- 18 |
US9944695 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
30- Apr -14 |
17- Apr- 18 |
US9944686 |
Treatment
of tumors with recombinant interferon alpha |
SUPERLAB
FAR EAST LIMITED |
28- Feb- 01 |
5- Sep -13 |
17- Apr- 18 |
US9944649 |
Compounds
and compositions as toll-like receptor 7 agonists |
Novartis
Ag |
1- May-
14 |
29- Apr -15 |
17- Apr- 18 |
US9943614 |
Cationic
steroid antimicrobial diagnostic, detection, screening and imaging methods |
BRIGHAM
YOUNG UNIVERSITY |
17- Jun- 08 |
16- Jun -09 |
17- Apr- 18 |
US9938300 |
Isothiazolopyrimidinones,
pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific
protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb- 15 |
4- Feb -16 |
10- Apr- 18 |
US9938275 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
23- Jan -17 |
10- Apr- 18 |
US9938258 |
Substituted
2,3-dihydrobenzofuranyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Nov- 12 |
27- Nov -13 |
10- Apr- 18 |
US9932351 |
Thienopyrimidinones
as ubiquitin-specific protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
3- Apr-
18 |
US9932323 |
Therapeutic
hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
Rutgers,
The State University of New Jersey |
11- Sep- 12 |
13- Jan -17 |
3- Apr-
18 |
US9931316 |
Antiviral
activity from medicinal mushrooms and their active constituents |
Not
Available |
31- Mar- 15 |
14- Sep -15 |
3- Apr-
18 |
US9926340 |
NAD
analogs and methods of using said NAD analogs in determining ribosylation of
proteins with PARP mutants |
Biolog
Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH |
8- Apr-
15 |
1- Apr -16 |
27- Mar -18 |
US9925215 |
Anionically
modified polyallylamine derivative, use of anionically modified
polyallylamine derivative as medicine, particularly for propylaxis and
treatment of infections of respiratory tract caused by human metapneumovirus
(hMPV), human rhinoviruses (HRV), and infection by influenza virus type A
(IAV) and pharmaceutical composition comprising the anionically modified
polyallylamine derivative |
UNIWERSYTET
JAGIELLONSKI |
29- Jul-14 |
25- Oct -17 |
27- Mar -18 |
US9920314 |
Compositions
for and methods of identifying antigens |
President
and Fellows of Harvard College |
21- Feb- 06 |
6- May -15 |
20- Mar -18 |
US9920128 |
Synthetic
antiserum for rapid-turnaround therapies |
The
Johns Hopkins University |
28- Jan- 15 |
20- Jan -16 |
20- Mar -18 |
US9919034 |
Methods
of treating and prophylactically protecting mammalian patients infected by
viruses classified in Baltimore group V |
TAMIR
BIOTECHNOLOGY, INC. |
28- Mar- 14 |
10- Jun -15 |
20- Mar -18 |
US9915613 |
Systems
and methods for distinguishing optical signals of different modulation
frequencies in an optical signal detector |
GEN-PROBE
INCORPORATED |
24- Feb- 11 |
21- Mar -14 |
13- Mar -18 |
US9914976 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA AGRICULTURAL
AND MECHANICAL UNIVERSITY (FA |
25- Mar- 11 |
27- May -16 |
13- Mar -18 |
US9913801 |
Treatment
of evolving bacterial resistance diseases including Klebsiella pneumoniae
with liposomally formulated glutathione |
YOUR
ENERGY SYSTEMS, LLC |
15- Feb- 13 |
15- Mar -13 |
13- Mar -18 |
US9909176 |
Efficient
deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq) |
The
Johns Hopkins University |
8- Sep-
14 |
1- Sep -15 |
6- Mar -18 |
US9908946 |
Generation
of binding molecules |
Merus
N.V. |
26- Sep- 11 |
16- Sep -15 |
6- Mar -18 |
US9908675 |
Powdered
pouch and method of making same |
MONOSOL,
LLC |
16- Apr- 12 |
19- Jul- 16 |
6- Mar -18 |
US9907796 |
Methods
of treating tumoral diseases, or bacterial or viral infections |
INHIBIKASE
THERAPEUTICS, INC. |
4- Oct-
12 |
15- Sep -16 |
6- Mar -18 |
US9895692 |
Sample-to-answer
microfluidic cartridge |
Micronics,
Inc. |
29- Jan- 10 |
5- Aug -15 |
20- Feb -18 |
US9895411 |
Analogs
of C5a and methods of using same |
BOARD
OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
29- Jun- 10 |
29- Jun -11 |
20- Feb -18 |
US9895341 |
Inflammation
and immunity treatments |
Ocean
Spray Cranberries, Inc. |
1- Apr-
11 |
30- Mar -12 |
20- Feb -18 |
US9894888 |
Transgenic
immunodeficient mouse expressing human SIRP-alpha |
INSTITUT
PASTEUR |
26- Mar- 12 |
26- Mar -13 |
20- Feb -18 |
US9890419 |
Nanoreporters
and methods of manufacturing and use thereof |
NanoString
Technologies, Inc. |
23- Dec- 05 |
20- May -16 |
13- Feb -18 |
US9890408 |
Multiple
displacement amplification |
IBIS
BIOSCIENCES, INC. |
15- Oct- 09 |
15- Oct -10 |
13- Feb -18 |
US9890362 |
Compositions,
methods and uses for inducing viral growth |
Takeda
Vaccines, Inc. |
5- Dec-
08 |
19- Sep -14 |
13- Feb -18 |
US9890361 |
Methods
for increasing the infectivity of viruses utilizing alkyne- modified fatty acids |
LIFE
TECHNOLOGIES CORPORATION |
26- Jan- 12 |
25- Jan -13 |
13- Feb -18 |
US9890206 |
H1N1
flu virus neutralizing antibodies |
Medigen
Biotechnology Corporation |
20- Aug- 15 |
20- Aug -15 |
13- Feb -18 |
US9890169 |
Triazolinone
compounds as HNE inhibitors |
CHIESI
FARMACEUTICI S.P.A. |
14- Dec- 15 |
12- Dec -16 |
13- Feb -18 |
US9890124 |
Benzazepine
sulfonamide compounds |
Hoffmann-La
Roche Inc. |
15- Dec- 15 |
14- Jun -17 |
13- Feb -18 |
US9889194 |
Immunogenic
composition for MERS coronavirus infection |
New
York Blood Center, Inc. |
1- Mar-
13 |
28- Feb -14 |
13- Feb -18 |
US9885092 |
Materials
and methods for detection of HPV nucleic acids |
QIAGEN
GAITHERSBURG INC. |
24- Feb- 11 |
23- Feb -12 |
6- Feb -18 |
US9885082 |
Embodiments
of a probe and method for targeting nucleic acids |
University
of Idaho |
19- Jul-11 |
19- Jul- 12 |
6- Feb -18 |
US9885037 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
6- Feb -18 |
US9884895 |
Methods
and compositions for chimeric coronavirus spike proteins |
The
University of North Carolina at Chapel Hill |
20- Mar- 14 |
20- Mar -15 |
6- Feb -18 |
US9884876 |
Anti-viral
compounds, pharmaceutical compositions, and methods of use thereof |
Kineta,
Inc. |
9- May-
14 |
8- May -15 |
6- Feb -18 |
US9884129 |
Release
of agents from cells |
The
Brigham and Women's Hospital, Inc. |
15- Oct- 09 |
5- Jan -15 |
6- Feb -18 |
US9884032 |
Esters of
short chains fatty acids for use in the treatment of immunogenic disorders |
PROPONENT
BIOTECH GMBH |
3- Oct-
12 |
3- Mar -16 |
6- Feb -18 |
US9884026 |
Modular
particles for immunotherapy |
YALE
UNIVERSITY |
1- Nov-
13 |
31- Oct -14 |
6- Feb -18 |
US9880151 |
Method of
determining, identifying or isolating cell-penetrating peptides |
Phylogica
Limited |
23- May- 11 |
23- May -12 |
30- Jan- 18 |
US9879026 |
Substituted
spirocycles |
Boehringer
Ingelheim International GmbH |
12- Sep- 14 |
29- Nov -16 |
30- Jan- 18 |
US9879003 |
Host
targeted inhibitors of dengue virus and other viruses |
Dana-Farber
Cancer Institute, Inc. |
11- Apr- 12 |
15- Mar -13 |
30- Jan- 18 |
US9878988 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
PARION
SCIENCES, INC. |
29- May- 12 |
5- Jan -16 |
30- Jan- 18 |
US9873678 |
Chemical
compounds |
AstraZeneca
AB |
18- Mar- 14 |
17- Mar -15 |
23- Jan- 18 |
US9873674 |
C-Rel
inhibitors and uses thereof |
CORNELL
UNIVERSITY |
21- Sep- 12 |
19- Sep -13 |
23- Jan- 18 |
US9872900 |
Nucleic
acid vaccines |
ModernaTX,
Inc. |
23- Apr- 14 |
5- Apr -16 |
23- Jan- 18 |
US9872898 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Founation |
24- Apr- 12 |
3- Oct -16 |
23- Jan- 18 |
US9872895 |
TLR5
ligands, therapeutic methods, and compositions related thereto |
Emory
University |
24- Sep- 10 |
20- Sep -11 |
23- Jan- 18 |
US9868952 |
Compositions
and methods for “resistance-proof†SiRNA therapeutics for influenza |
Sirnaomics,
Inc. |
8-Jul- 12 |
7- Jul- 13 |
16- Jan- 18 |
US9868740 |
Pyrimidinone
compounds which are HNE inhibitors |
CHIESI
FARMACEUTICI S.p.A. |
12- Jun- 14 |
12- Jun -14 |
16- Jan- 18 |
US9868736 |
Deubiquitinase
inhibitors and methods for use of the same |
THE
REGENTS OF THE UNIVERSITY OF MICHIGAN |
10- Oct- 13 |
10- Oct -14 |
16- Jan- 18 |
US9867882 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
25- Aug -15 |
16- Jan- 18 |
US9867877 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
22- Nov -16 |
16- Jan- 18 |
US9862706 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
9- Jan-
18 |
US9861614 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
23- Jun -15 |
9- Jan-
18 |
US9856254 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
13- Jun -16 |
2- Jan-
18 |
US9856241 |
Substituted
benzofuranyl and benzoxazolyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
3-Jul- 13 |
3- Jul- 14 |
2- Jan-
18 |
US9856228 |
Peptidyl
nitril compounds as dipeptidyl peptidase I inhibitors |
PROZYMEX
A/S |
9- Sep-
13 |
8- Sep -14 |
2- Jan-
18 |
US9856224 |
Stable
sodium channel blockers |
PARION
SCIENCES, INC. |
30- Jun- 14 |
30- Jan -17 |
2- Jan-
18 |
US9855287 |
Anti-viral
azide containing compounds |
LIFE
TECHNOLOGIES CORPORATION |
28- Jul-10 |
20- Aug -15 |
2- Jan-
18 |
US9855284 |
Pharmaceutical
compositions and methods |
Pop
Test Oncology LLC |
3- Aug-
15 |
6- Dec -16 |
2- Jan-
18 |
US9849143 |
Broad
spectrum antiviral and methods of use |
The
Burlington HC Research Group, Inc. |
17- Apr- 06 |
16- Feb -17 |
26- Dec -17 |
US9845342 |
Fusion
proteins, recombinant bacteria, and methods for using recombinant bacteria |
Spogen
Biotech Inc. |
17- Sep- 14 |
17- Sep -15 |
19- Dec -17 |
US9840731 |
Preservation
of biological materials in non-aqueous fluid media |
Gentegra,
LLC |
14- Mar- 13 |
14- Mar -14 |
12- Dec -17 |
US9840719 |
Variant
AAV and compositions, methods and uses for gene transfer to cells, organs and
tissues |
The
Children's Hospital of Philadelphia |
22- Jul-13 |
22- Jul- 14 |
12- Dec -17 |
US9840491 |
Quinazolinones
and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
FORMA
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
12- Dec -17 |
US9839687 |
Acetylenedicarboxyl
linkers and their uses in specific conjugation of a cell-binding molecule |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
15- Jul- 15 |
12- Dec -17 |
US9834812 |
Probe
kit for detecting a single strand target nucleotide sequence |
Fondazione
Istituto Italiano Di Tecnologia |
27- Dec- 12 |
27- Dec -13 |
5- Dec -17 |
US9834791 |
CRISPR-related
methods and compositions with governing gRNAS |
Editas
Medicine, Inc. |
7- Nov-
13 |
7- Nov -14 |
5- Dec -17 |
US9834757 |
Hand,
foot, and mouth vaccines and methods of manufacture and use thereof |
Takeda
Vaccines, Inc. |
7- Nov-
14 |
6- Nov -15 |
5- Dec -17 |
US9834595 |
Amino
acid sequences directed against envelope proteins of a virus and polypeptides
comprising the same for the treatment of viral diseases |
Ablynx
N.V. |
5- Jun- 08 |
29- Oct -15 |
5- Dec -17 |
US9833504 |
Virus-like
particles and process for preparing same |
Folia
Biotech Inc. |
13- May- 11 |
1- May -12 |
5- Dec -17 |
US9833492 |
Combinations
of a caspase inhibitor and an antiviral agent |
Centre
National de la Recherche Scientifique |
2- Nov-
07 |
15- May -15 |
5- Dec -17 |
US9832998 |
Antiviral
compositions |
Long
Island University |
30- May- 07 |
19- Mar -15 |
5- Dec -17 |
US9828382 |
Pyrimidinone
compounds as human neutrophil elastase inhibitors |
Chiesi
Farmaceutici S.p.A. |
18- Dec- 12 |
10- May -16 |
28- Nov -17 |
US9828379 |
Pyrrolo-pyrrole
carbamate and related organic compounds, pharmaceutical compositions, and
medical uses thereof |
ABIDE
THERAPEUTICS, INC. |
3-Jul- 13 |
1- Jul- 14 |
28- Nov -17 |
US9828370 |
Compositions
and methods for inhibiting kinases |
INHIBIKASE
THERAPEUTICS, INC. |
23- Apr- 15 |
22- Apr -16 |
28- Nov -17 |
US9828346 |
N-myristoyl
transferase inhibitors |
University
of Dundee |
2- Sep-
08 |
31- Aug -15 |
28- Nov -17 |
US9828342 |
Isatin
derivatives, pharmaceutical compositions thereof, and methods of use thereof |
CITY
OF HOPE |
24- Feb- 12 |
25- Feb -13 |
28- Nov -17 |
US9827190 |
Intradermal
delivery of immunological compositions comprising toll- like receptor 7
agonists |
GLAXOSMITHKLINE
BIOLOGICALS SA |
1- Feb-
13 |
30- Jan -14 |
28- Nov -17 |
US9822339 |
Means and
methods for influencing the stability of antibody producing cells |
ACADEMISCH
MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM |
9- Dec-
05 |
26- Aug -15 |
21- Nov -17 |
US9822173 |
Heterodimeric
immunoglobulins |
AMGEN
INC. |
21- Nov- 12 |
21- Nov -13 |
21- Nov -17 |
US9822165 |
Hydrocarbon
stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external
region |
DANA-FARBER
CANCER INSTITUTE, INC. |
18- Jun- 09 |
18- Jun -10 |
21- Nov -17 |
US9822155 |
Method of
preventively treating a subject at the risk of developing infections of a
respiratory virus |
Xiangxue
Group (Hong Kong) Company Limited |
9- May-
13 |
23- Aug -16 |
21- Nov -17 |
US9822127 |
GAK
modulators as antivirals |
The Board
of Trustees of the Leland Stanford Junior University |
23- Jul-14 |
23- Jul- 15 |
21- Nov -17 |
US9822065 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
14- Feb -17 |
21- Nov -17 |
US9821052 |
Reverse
genetics systems |
Seqirus
UK Limited |
31- Jul-09 |
30- Jul- 10 |
21- Nov -17 |
US9821051 |
Reducing
hospitalization in elderly influenza vaccine recipients |
Seqirus
UK Limited |
28- Oct- 10 |
21- Oct -11 |
21- Nov -17 |
US9816078 |
Compositions
for increasing polypeptide stability and activity, and related methods |
SOLIS
BIODYNE OÜ |
19- Nov- 09 |
11- Mar -16 |
14- Nov -17 |
US9815886 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
8- Jan -15 |
14- Nov -17 |
US9815805 |
Certain
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as
dipeptidyl peptidase 1 inhibitors |
ASTRAZENECA
AB |
24- Jan- 14 |
8- Nov -16 |
14- Nov -17 |
US9814777 |
Targeting
lipids |
Arbutus
Biopharma Corporation |
4- Dec-
07 |
22- Oct -13 |
14- Nov -17 |
US9810683 |
Use of
live cell inteferometry with reflective floor of observation chamber to
determine changes in mass of mammalian cells |
The
Regents of the University of California |
6- May-
09 |
25- Nov -13 |
7- Nov -17 |
US9809845 |
Methods
and reagents for amplifying nucleic acids |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
6- Aug-
12 |
6- Aug -12 |
7- Nov -17 |
US9809796 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
18- May -17 |
7- Nov -17 |
US9809632 |
Universal
protein tag for double stranded nucleic acid delivery |
University
of Washington Through its Center for Commercialization |
23- Oct- 13 |
22- Oct -14 |
7- Nov -17 |
US9809591 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
5- Oct -15 |
7- Nov -17 |
US9808490 |
Induced
hepatocytes and uses thereof |
ACCELERATED
BIOSCIENCES CORP. |
26- Nov- 14 |
25- Nov -15 |
7- Nov -17 |
US9803236 |
Microarray-based
assay integrated with particles for analyzing molecular interactions |
CapitalBio
Corporation |
6- Aug-
10 |
6- Aug -10 |
31- Oct- 17 |
US9803197 |
Particle-nucleic
acid conjugates and therapeutic uses related thereto |
Emory
University |
25- Jun- 12 |
27- Feb -13 |
31- Oct- 17 |
US9802937 |
Substituted
pyrazolo{4,3-D}pyrimidines as kinase inhibitors |
ORIGENIS
GMBH |
21- Apr- 11 |
23- Apr -12 |
31- Oct- 17 |
US9802919 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
31- Oct- 17 |
US9801948 |
Antimicrobial
compositions and methods of use thereof |
Yale
University |
21- Sep- 11 |
21- Sep -12 |
31- Oct- 17 |
US9801947 |
Methods
and compositions for enhancing immune response |
3M
INNOVATIVE PROPERTIES COMPANY |
10- Apr- 03 |
6- Oct -14 |
31- Oct- 17 |
US9801935 |
Soluble
needle arrays for delivery of influenza vaccines |
SEQIRUS
UK LIMITED |
20- Aug- 10 |
11- Oct -16 |
31- Oct- 17 |
US9801897 |
Delivery
of RNA to trigger multiple immune pathways |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
6- Jul- 11 |
31- Oct- 17 |
US9797000 |
Non-target
amplification method for detection of RNA splice-forms in a sample |
QIAGEN
GAITHERSBURG INC. |
1- May-
09 |
30- Apr -10 |
24- Oct- 17 |
US9796979 |
Oligonucleotide
modulators of the toll-like receptor pathway |
Quark
Pharmaceuticals Inc. |
3- Mar-
11 |
28- Jul- 16 |
24- Oct- 17 |
US9796735 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
20- Jun- 07 |
7- Nov -14 |
24- Oct- 17 |
US9795669 |
Lipidated
immune response modifier compound compositions, formulations, and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
17- Aug- 10 |
15- Dec -15 |
24- Oct- 17 |
US9795668 |
Delivery
of self-replicating RNA using biodegradable polymer particles |
GlaxoSmithKline
Biologicals S.A. |
6-Jul- 10 |
23- Nov -15 |
24- Oct- 17 |
US9795666 |
High-yield
transgenic mammalian expression system for generating virus-like particles |
Academia
Sinica |
5- Sep-
06 |
11- Feb -15 |
24- Oct- 17 |
US9791437 |
Multianalyte
assay |
Nexus
Dx, Inc. |
30- Apr- 07 |
15- Jun -15 |
17- Oct- 17 |
US9789180 |
D-amino
acid derivative-modified peptidoglycan and methods of use thereof |
The
Regents of the University of California |
30- Nov- 12 |
31- Mar -16 |
17- Oct- 17 |
US9786050 |
Stain-free
histopathology by chemical imaging |
The
Board of Trustees of the University of Illinois |
15- Mar- 13 |
14- Mar -14 |
10- Oct- 17 |
US9783595 |
Neutralizing
GP41 antibodies and their use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
7- Nov-
11 |
2- Aug -16 |
10- Oct- 17 |
US9782470 |
Method
of obtaining thermostable dried vaccine formulations |
Merck
Sharp & Dohme Corp. |
16- Oct- 13 |
13- Oct -14 |
10- Oct- 17 |
US9782434 |
Methods
of treating or preventing inflammation and hypersensitivity with oxidative
reductive potential water solution |
Sonoma
Pharmaceuticals, Inc. |
20- Jan- 06 |
7- Jul- 15 |
10- Oct- 17 |
US9770504 |
Generating
peptoid vaccines |
The
Board of Regents of the University of Texas System |
3- May-
13 |
2- May -14 |
26- Sep -17 |
US9770463 |
Delivery
of RNA to different cell types |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
7- Jun -11 |
26- Sep -17 |
US9765395 |
System
and method for DNA sequencing and blood chemistry analysis |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
10- Apr -15 |
19- Sep -17 |
US9765133 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
29- Apr -14 |
19- Sep -17 |
US9765071 |
Substituted
imidazo ring systems and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
25- Nov- 03 |
14- Mar -16 |
19- Sep -17 |
US9764027 |
Outer
membrane vesicles |
GLAXOSMITHKLINE
BIOLOGICALS SA |
18- Sep- 12 |
18- Sep -13 |
19- Sep -17 |
US9759723 |
B-cell
antigen presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
21- Mar -16 |
12- Sep -17 |
US9758840 |
Parasite
detection via endosymbiont detection |
IBIS
BIOSCIENCES, INC. |
14- Mar- 10 |
11- Mar -11 |
12- Sep -17 |
US9758820 |
Organism
identification panel |
BioFire
Diagnostics, LLC |
2- Apr-
07 |
1- Apr -08 |
12- Sep -17 |
US9758775 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
14- Apr -14 |
12- Sep -17 |
US9758568 |
Oligopeptide-free
cell culture media |
Baxalta
GmbH |
4- Jan- 06 |
16- Nov -15 |
12- Sep -17 |
US9758553 |
Yeast
strain for the production of proteins with terminal alpha-1,3- linked
galactose |
MERCK
SHARP & DOHME CORP. |
30- May- 08 |
2- Jul- 14 |
12- Sep -17 |
US9757478 |
Mutant
protease biosensors with enhanced detection characteristics |
Promega
Corporation |
11- May- 10 |
7- Jan -16 |
12- Sep -17 |
US9757470 |
Peptides
for assisting delivery across the blood brain barrier |
Children's
Medical Center Corporation |
22- May- 06 |
30- Apr -14 |
12- Sep -17 |
US9757446 |
Influenza
virus vectors and uses therefor |
FLUGEN,
INC. |
17- Mar- 14 |
13- Mar -15 |
12- Sep -17 |
US9757407 |
Treatment
of viral infections by modulation of host cell metabolic pathways |
The
Trustees of Princeton University |
1- Jun-
07 |
21- Dec -15 |
12- Sep -17 |
US9751945 |
Sortase-modified
VHH domains and uses thereof |
Whitehead
Institute for Biomedical Research |
13- Apr- 12 |
15- Apr -13 |
5- Sep -17 |
US9750798 |
Bunyaviruses
with segmented glycoprotein precursor genes and methods for generating these
viruses |
STICHTING
WAGENINGEN RESEARCH |
21- May- 13 |
21- May -14 |
5- Sep -17 |
US9750797 |
Sustained
release vaccine composition |
VIRBAC
CORPORATION |
16- Jun- 04 |
16- Jun -05 |
5- Sep -17 |
US9750690 |
Circulation
of components during microfluidization and/or homogenization of emulsions |
NOVARTIS
AG |
3- Dec-
09 |
5- Sep -14 |
5- Sep -17 |
US9746985 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
25- Feb- 08 |
20- Apr -11 |
29- Aug -17 |
US9746459 |
Antigen
presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
11- Oct -13 |
29- Aug -17 |
US9745306 |
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-
D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one
derivatives and their use as phosphoinositide 3-kinase inhibitors |
Respivert
Limited |
15- Mar- 13 |
14- Mar -14 |
29- Aug -17 |
US9744231 |
Quality
control methods for oil-in-water emulsions containing squalene |
NOVARTIS
AG |
8- Nov-
06 |
27- Aug -13 |
29- Aug -17 |
US9744229 |
Vaccines
and immunotherapeutics using IL-28 and compositions and methods of using the
same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
4- Apr-
08 |
28- Apr -14 |
29- Aug -17 |
US9744183 |
Nucleic
acid prodrugs and methods of use thereof |
WAVE
LIFE SCIENCES LTD. |
6-Jul- 09 |
6- Jul- 10 |
29- Aug -17 |
US9738894 |
Short
interfering RNA (siRNA) analogues |
Roche
Innovation Center Copenhagen A/S |
21- Mar- 03 |
28- Mar -16 |
22- Aug -17 |
US9738624 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
21- Jun- 13 |
20- Jun -14 |
22- Aug -17 |
US9737618 |
Adeno-associated
virus (AAV) glades, sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
30- Sep- 03 |
20- Jul- 15 |
22- Aug -17 |
US9737593 |
Carbon
nanotube compositions and methods of use thereof |
Yale
University |
19- Mar- 08 |
15- Mar -13 |
22- Aug -17 |
US9730997 |
Alphavirus
vectors for respiratory pathogen vaccines |
Novartis
Vaccines and Diagnostics, Inc. |
21- May- 04 |
20- Aug -14 |
15- Aug -17 |
US9730912 |
Pharmaceutical
compounds |
ASTEX
THERAPEUTICS LIMITED |
12- Oct- 06 |
12- Oct -07 |
15- Aug -17 |
US9727810 |
Spatially
addressable molecular barcoding |
Cellular
Research, Inc. |
27- Feb- 15 |
26- Feb -16 |
8- Aug -17 |
US9726607 |
Systems
and methods for detecting multiple optical signals |
GEN-PROBE
INCORPORATED |
10- Mar- 05 |
3- Mar -14 |
8- Aug -17 |
US9725770 |
Methods
and compositions for identification of source of microbial contamination in a
sample |
The
Regents of the University of California |
6- Mar-
12 |
6- Mar -13 |
8- Aug -17 |
US9725487 |
Compositions
and methods for measles virus inhibition |
Autoimmune
Technologies, LLC |
4- Nov-
03 |
13- May -15 |
8- Aug -17 |
US9719106 |
Tissue
preferential codon modified expression cassettes, vectors containing same,
and uses thereof |
The
Trustees of the University of Pennsylvania |
29- Apr- 13 |
29- Apr -14 |
1- Aug -17 |
US9719083 |
Bioagent
detection methods |
IBIS
BIOSCIENCES, INC. |
8- Mar-
09 |
8- Mar -10 |
1- Aug -17 |
US9718774 |
Indole
carboxamide derivatives as P2X7 receptor antagonist |
IDORSIA
PHARMACEUTICALS LTD |
12- Dec- 12 |
11- Dec -13 |
1- Aug -17 |
US9717755 |
Method
of treating inflammation |
Cytosorbents
Corporation |
1- Apr-
10 |
1- Apr -11 |
1- Aug -17 |
US9717749 |
Production
of stable non-polyadenylated RNAs |
Massachusetts
Institute of Technology |
16- Oct- 12 |
16- Oct -13 |
1- Aug -17 |
US9717732 |
Drug
combination |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
1- Aug -17 |
US9714411 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
30- Nov -15 |
25- Jul- 17 |
US9714283 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
2- Jul- 15 |
25- Jul- 17 |
US9714226 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
13- Nov -15 |
25- Jul- 17 |
US9713641 |
Anti-TIGIT
antigen-binding proteins and methods of use thereof |
Potenza
Therapeutics, Inc. |
13- Feb- 17 |
13- Feb -17 |
25- Jul- 17 |
US9713606 |
Methods
for treating pulmonary emphysema using substituted 2-
Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
1- Dec -15 |
25- Jul- 17 |
US9708375 |
Inhibitory
polypeptides specific to WNT inhibitors |
Amgen
Inc. |
15- Mar- 13 |
14- Mar -14 |
18- Jul- 17 |
US9707278 |
Methods
of modulating immune responses by modifying Akt3 bioactivity |
Augusta
University Research Institute, Inc. |
17- Apr- 14 |
17- Apr -15 |
18- Jul- 17 |
US9701736 |
Influenza
hemagglutinin-specific monoclonal antibodies for preventing and treating
influenza virus infection |
New
York Blood Center, Inc. |
20- Oct- 10 |
9- Oct -14 |
11- Jul- 17 |
US9701638 |
Therapeutic
hydroxyquinolones |
Rutgers,
The State University of New Jersey |
9- Nov-
12 |
8- Nov -13 |
11- Jul- 17 |
US9700616 |
Arranging
interaction and back pressure chambers for microfluidization |
NOVARTIS
AG |
3- Dec-
09 |
22- Mar -16 |
11- Jul- 17 |
US9700614 |
Intranasal
vaccination dosage regimen |
Eurocine
Vaccines AB |
17- Dec- 12 |
17- Dec -13 |
11- Jul- 17 |
US9700558 |
Drug
combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
11- Jul- 17 |
US9696247 |
Sample
fixation and stabilisation |
RNASSIST
LTD. |
1- Mar-
13 |
28- Feb -14 |
4- Jul- 17 |
US9695445 |
Method
for production of reprogrammed cell using chromosomally unintegrated virus
vector |
ID
Pharma Co., Ltd. |
16- Jul-08 |
29- Jul- 15 |
4- Jul- 17 |
US9695135 |
Therapeutic
catechols |
Rutgers,
The State University of New Jersey |
12- May- 14 |
11- May -15 |
4- Jul- 17 |
US9695134 |
3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-
2-carboxamide compounds |
Parion
Sciences, Inc. |
17- Dec- 12 |
8- Jan -15 |
4- Jul- 17 |
US9689018 |
Mixed
cell diagnostic systems for detection of respiratory, herpes and enteric
viruses |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
4- Aug -14 |
27- Jun- 17 |